Product Description:

Health Male Sex Hormones Raloxifene Against Estrogen-Sensitive Cancers

Quick Detail:

Alias: Keoxifene hydrochloride; Raloxifene hydrochloride; Raloxifene HC; RALOXIFENE HCL; ly156758; KEOXIFENE;KEOXIFENE HYDROCHLORIDE;LY 139481;AKOS 92138
CAS No: 82640-04-8
MF: C28H28ClNO4S
MW: 510.04
Purity: 98.0%~103.0%

Molecular Structure:

Classes: Pharmaceutical Grade

Type: Antineoplastic Agents
Appearance: Light yellow crystalline powder,

Storage: Shading, confined preservation

Packaging: 5kg/tin or according to your requriement
USES:  Raloxifene will be like as effective, and less adverse effects.

Description:

EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds

The chemical designation , [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S.HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale-yellow solid that is very slightly soluble in water.

Applications:

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.
in 2006, the National Cancer Institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk, Raloxifene  is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.

May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e. G., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.

EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrous lactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide.